These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35614177)

  • 1. High CRP-albumin ratio predicts poor prognosis in transplant ineligible elderly patients with newly diagnosed acute myeloid leukemia.
    Senjo H; Onozawa M; Hidaka D; Yokoyama S; Yamamoto S; Tsutsumi Y; Haseyama Y; Nagashima T; Mori A; Ota S; Sakai H; Ishihara T; Miyagishima T; Kakinoki Y; Kurosawa M; Kobayashi H; Iwasaki H; Hashimoto D; Kondo T; Teshima T
    Sci Rep; 2022 May; 12(1):8885. PubMed ID: 35614177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretransplantation Inflammatory and Nutritional Status in Elderly Allogeneic Hematopoietic Stem Cell Transplantation: Prognostic Value of C-Reactive Protein-to-Albumin Ratio.
    Miyazaki T; Tachibana T; Suzuki T; Izumi A; Fujimaki K; Sato S; Tamai Y; Michishita Y; Suzuki T; Ishii R; Hirasawa A; Hashimoto C; Kabasawa N; Inoue Y; Ishiyama T; Yamamoto K; Kanamori H; Tanaka M; Nakajima H
    Transplant Cell Ther; 2024 Apr; 30(4):400.e1-400.e9. PubMed ID: 38253183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel nutritional index "simplified CONUT" and the disease risk index independently stratify prognosis of elderly patients with acute myeloid leukemia.
    Senjo H; Onozawa M; Hidaka D; Yokoyama S; Yamamoto S; Tsutsumi Y; Haseyama Y; Nagashima T; Mori A; Ota S; Sakai H; Ishihara T; Miyagishima T; Kakinoki Y; Kurosawa M; Kobayashi H; Iwasaki H; Hashimoto D; Kondo T; Teshima T
    Sci Rep; 2020 Nov; 10(1):19400. PubMed ID: 33173122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Prognostic Significance of C-Reactive Protein to Albumin Ratio in Newly Diagnosed Acute Myeloid Leukaemia Patients.
    Dou L; Shi M; Song J; Niu X; Niu J; Wei S; Li D; Bai Y; Sun K
    Cancer Manag Res; 2022; 14():303-316. PubMed ID: 35115829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
    Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic hematopoietic stem cell transplant overcomes poor prognosis of acute myeloid leukemia with myelodysplasia-related changes.
    Ikegawa S; Doki N; Kurosawa S; Yamaguchi T; Sakaguchi M; Harada K; Yamamoto K; Hino Y; Shingai N; Senoo Y; Watanabe K; Igarashi A; Najima Y; Kobayashi T; Kakihana K; Sakamaki H; Ohashi K
    Leuk Lymphoma; 2016; 57(1):76-80. PubMed ID: 26084204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of adult patients with acute myeloid leukemia and unsuccessful cytogenetic analysis undergoing allogeneic hematopoietic stem cell transplantation.
    Vasudevan Nampoothiri R; Chen S; Pasic I; Al-Shaibani Z; Lam W; Michelis FV; Kim DDH; Viswabandya A; Gerbitz A; Lipton JH; Kumar R; Mattsson J; Law AD
    Hematol Oncol Stem Cell Ther; 2021 Jun; 14(2):134-140. PubMed ID: 33049225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of the CFA ratio for newly diagnosed acute myeloid leukemia: A multicenter retrospective study.
    Sakuma T; Fujisawa S; Tanaka M; Hagihara M; Fujita H; Fujimaki K; Katsuki K; Akimoto M; Tanaka M; Matsumura A; Teshigawara H; Suzuki T; Teranaka H; Nakajima Y; Miyazaki T; Tachibana T; Matsumoto K; Sakai R; Kanamori H; Nakajima H
    Hematol Oncol; 2024 Jan; 42(1):e3228. PubMed ID: 37731313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of pre-transplant disease burden on the outcome of allogeneic hematopoietic stem cell transplant in refractory and relapsed acute myeloid leukemia: a single-center study.
    Tian H; Chen GH; Xu Y; Ma X; Chen F; Yang Z; Jin ZM; Qiu HY; Sun AN; Wu DP
    Leuk Lymphoma; 2015 May; 56(5):1353-61. PubMed ID: 25204372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Superiority of Allogeneic Hematopoietic Stem Cell Transplantation Over Chemotherapy Alone in the Treatment of Acute Myeloid Leukemia Patients with Mixed Lineage Leukemia (MLL) Rearrangements.
    Yang H; Huang S; Zhu CY; Gao L; Zhu HY; Lv N; Jing Y; Yu L
    Med Sci Monit; 2016 Jul; 22():2315-23. PubMed ID: 27373985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.
    Song Y; Zhang W; He X; Liu X; Yang P; Wang J; Hu K; Liu W; Zhang X; Jing H; Yuan X
    J Transl Med; 2019 May; 17(1):166. PubMed ID: 31109331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic hematopoietic stem cell transplantation could improve the survival of acute myeloid leukemia patients with ASXL1 mutations.
    Zhou L; An J; Hou C; Ding Z; Qiu H; Tang X; Sun A; Chen S; Xu Y; Liu T; Wu D
    Hematology; 2021 Dec; 26(1):340-347. PubMed ID: 33840380
    [No Abstract]   [Full Text] [Related]  

  • 13. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
    Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
    BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory/relapsed acute myeloid leukemia not in remission status.
    Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
    Ann Hematol; 2020 Dec; 99(12):2911-2925. PubMed ID: 33000361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Charlson comorbidity index predicts outcomes of elderly after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome.
    Chien SH; Yao M; Li CC; Chang PY; Yu MS; Huang CE; Tan TD; Lin CH; Yeh SP; Li SS; Wang PN; Liu YC; Gau JP
    J Formos Med Assoc; 2021 Dec; 120(12):2144-2152. PubMed ID: 33423899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Kong J; Gao MG; Qin YZ; Wang Y; Yan CH; Sun YQ; Chang YJ; Xu LP; Zhang XH; Liu KY; Huang XJ; Zhao XS
    BMC Cancer; 2022 Jan; 22(1):11. PubMed ID: 34979982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regional differences in access to hematopoietic stem cell transplantation among pediatric patients with acute myeloid leukemia.
    Truong TH; Pole JD; Bittencourt H; Schechter T; Cuvelier GDE; Paulson K; Rayar M; Mitchell D; Schultz KR; O'Shea D; Barber R; Sung L
    Pediatr Blood Cancer; 2020 Jul; 67(7):e28263. PubMed ID: 32323913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic index for patients with relapsed or refractory acute myeloid leukemia who underwent hematopoietic cell transplantation: a KSGCT multicenter analysis.
    Tachibana T; Kanda J; Ishizaki T; Najima Y; Tanaka M; Doki N; Fujiwara SI; Kimura SI; Onizuka M; Takahashi S; Saito T; Mori T; Fujisawa S; Sakaida E; Matsumoto K; Aotsuka N; Goto M; Watanabe R; Shono K; Usuki K; Tsukada N; Kanamori H; Kanda Y; Okamoto S; ;
    Leukemia; 2019 Nov; 33(11):2610-2618. PubMed ID: 31147621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia.
    Fleischmann M; Schnetzke U; Frietsch JJ; Sayer HG; Schrenk K; Hammersen J; Glaser A; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2022 Jun; 148(6):1481-1492. PubMed ID: 34297206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.